Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0600

+16.5%

Nov 26 3:10 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Max Fletcher who wrote (11336)	6/6/2012 9:20:06 AM
From: NTTG	of 13111

Polynoma has initiated their PIII SPA melanoma vaccine trial for stage IIb,IIc or III patients. Trial is based on positive findings for efficacy (significant improvement in recurrence free survival and overall survival compared to placebo) and safety data from 2 PII randomized, controlled studies; and treatment of over 650 patients to date. The PIII has a phase I run in element to evaluate dosing in 99 patients, and a second phase that will randomize 960 patients to a placebo or vaccine arm. These are the kinds of trials that catch media attention.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next